Today the Centers for Disease Control and Prevention (CDC) said that masks should be used by those vaccinated against the coronavirus in public indoor spaces in parts of the country where the virus is surging.
Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs)
JAMA has published the findings of trial wherein the anti–interleukin-1β antibody canakinumab (CAN) failed to improve survival in patients hospitalized with severe COVID-19.
MMWR review of the risk of myocarditis and pericarditis reports a June 23, 2021 recommendation by the Advisory Committee on Immunization Practices that the benefits of COVID-19 vaccination clearly outweighed the risks of myocarditis after vaccination.
Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.
How risky are family gatherings, birthday parties and informal social gatherings? A cross-sectional analysis suggests that birthdays may be associated with increased rates of COVID-19 infection within households where there is a high COVID-19 prevalence in the population.
The NEJM has published results of a real-world efficacty trial showing that COVID infected children with the multisystem inflammatory syndrome in children (MIS-C) respond better to initial IVIG plus glucocorticoids (than IVIG alone) which was associated with less subsequent cardiovascular complic
NEJM has published the results of an observational trial wherein tofacitinib given to patients hospitalized with Covid-19 pneumonia, was shown to significantly lower risk of death or respiratory failure.
Lots of presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4.
Links:
Dr. John Cush @RheumNow ( View Tweet )
Links:
Dr. John Cush @RheumNow ( View Tweet )
Links:
Dr. John Cush @RheumNow ( View Tweet )
Daniel Aletaha @DanielAletaha ( View Tweet )
Links:
Links:
Dr. John Cush @RheumNow ( View Tweet )
Links:
Links:
Links:
Links:
Dr. John Cush @RheumNow ( View Tweet )
